Nasdaq dbtx.

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Nasdaq dbtx. Things To Know About Nasdaq dbtx.

Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Nov 8, 2021 · Find the latest press releases from Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com. Decibel Therapeutics (NASDAQ:DBTX) posts positive preclinical data supporting the company’s gene therapy product candidate, DB-OTO, a potential treatment for individuals with hearing loss due to ...BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Financial Performance. In 2022, REGN's revenue was $12.17 billion, a decrease of -24.26% compared to the previous year's $16.07 billion. Earnings were $4.34 billion, a decrease of -46.28%. Financial Statements.Director. 02/17/2021. Acquisition (Non Open Market) Indirect. 3,278,526. 2,732,106. Back to DBTX Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the ...Find the latest Financials data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.

Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage ...BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of Directors.“We are pleased to welcome …BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...10-Nov-2023 ... ... NASDAQ:DBTX),一家致力于发现和开发恢复和改善听力和平衡的变革性治疗方法的临床生物技术公司,并附带一项额外的不可交易或有价值权(CVR),在 ...BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Company profile page for Decibel Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information

Based on analysts offering 12 month price targets for DBTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Decibel Therapeutics, Inc. (NASDAQ: DBTX) Decibel Therapeutics has agreed to merge with Regeneron Pharmaceuticals. Under the proposed transaction, Decibel shareholders will receive $4.00 in cash ...Stock Symbol NASDAQ:DBTX ; Company Type For Profit; Contact Email [email protected]; Phone Number (617) 370-8701; Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction …BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Mar 30, 2023 · BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Translating rapid advances in hearing science to meet the urgent needs of hundreds of millions worldwide with disabling hearing loss.BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. (NASDAQ:DBTX) rose 13.5% to close at $4.88. Decibel Therapeutics recently reported top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB ...Dropbox, Inc. (NASDAQ:DBX) is an American software company that operates a global collaboration platform. DBX has over 700 million registered users across about 180 countries, providing cloud storage, file synchronization, personal cloud, and client software. The software company has a large market cap, currently valued at $7.4 billion.BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Cash Position: As of March 31, 2023, cash, cash equivalents and available-for-sale securities were $87.9 million, compared to $104.6 million as of December 31, 2022. Research and Development ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Nov 22, 2021 · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss. Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage ...BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Decibel Therapeutics, Inc. (Nasdaq - DBTX) Under the terms of the Merger Agreement, Decibel will be acquired by Regeneron Pharmaceuticals, Inc. (Nasdaq - REGN). Decibel shareholders will receive ...

TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company ...Aug 9, 2023 · The deal also has an additional contingent payment of $3.50 per share for DBTX stock if certain milestones are met. At the $4 price for DBTX stock, this offer represents a 43.3% premium over its ... BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Follow. BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to ...The deal also has an additional contingent payment of $3.50 per share for DBTX stock if certain milestones are met. At the $4 price for DBTX stock, this offer represents a 43.3% premium over its ...BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Feb 9, 2022 · BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering an...

Decibel Therapeutics, Inc. Common Stock (DBTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. Feb 10, 2022 · Decibel Therapeutics Inc (NASDAQ: DBTX) announced the presentation of preclinical data on DB-OTO, its lead gene therapy product candidate. DB-OTO is a dual-vector adeno-associated candidate ... DROPBOX INC ( DBX) is a mid-cap growth stock in the Software & Programming industry. The rating using this strategy is 93% based on the firm’s underlying fundamentals and the stock’s valuation ...The Decibel Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Instagram:https://instagram. dimchaehigh reit dividendsteam powered carriageschwab index funds best 09-Aug-2023 ... Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Decibel Therapeutics, Inc. (NASDAQ: DBTX) to Regeneron ... eras stockmlpdx stock Nov 30, 2023 · Decibel Therapeutics Description. Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support ... top 10 dividend paying utility stocks BOSTON, March 18, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a ...Nov 2, 2022 · Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ...